1. IMS Health. Developments in cancer treatments, market dynamics, patient access and value. Global oncology trend report 2015. 2015 May 2015 [cited 2016 21 June]; Available from: http://keionline.org/sites/default/files/IIHI_Oncology_Trend_Report_2015.pdf .
2. IMS Health. Medicines use and spending in the U.S. A review of 2015 and outlook to 2020. 2016 April 2016 [cited 2016 21 June]; Available from: https://morningconsult.com/wp-content/uploads/2016/04/IMS-Institute-US-Drug-Spending-2015.pdf .
3. IMS Health. Top 20 global products 2015. 2015 December 2015 [cited 2016 21 June]; Available from: http://www.imshealth.com/files/web/Corporate/News/Top-Line%20Market%20Data/Top_20_Global_Products_2015.pdf .
4. Gori S, Di Maio M, Pinto C, Alabiso O, Baldini E, Beretta GD, et al. Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society Of Medical Oncology (AIOM). Tumori. 2010;96(6):1010–5.
5. Park T, Griggs SK, Suh DC. Cost effectiveness of monoclonal antibody therapy for rare diseases: a systematic review. BioDrugs. 2015;29(4):259–74.